Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0JW6R
|
|||
| Drug Name |
LAM-002
|
|||
| Indication | Chronic lymphocytic leukaemia [ICD-11: 2A82.0; ICD-10: C83.0, C91.1] | Phase 2 | [1] | |
| Non-hodgkin lymphoma [ICD-11: 2B33.5; ICD-10: C82-C85; ICD-9: 200, 202] | Phase 2 | [1] | ||
| B-cell non-hodgkin lymphoma [ICD-11: 2B33.5; ICD-10: C85.9] | Phase 1 | [2] | ||
| Company |
LAM Therapeutics Guilford, CT
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Phosphatidylinositol-3-phosphate 5-kinase (PIP5K3) | Target Info | Inhibitor | [2] |
| KEGG Pathway | Inositol phosphate metabolism | |||
| Metabolic pathways | ||||
| Phosphatidylinositol signaling system | ||||
| Phagosome | ||||
| Regulation of actin cytoskeleton | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02594384) A Phase I Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A In Patients With Non-Hodgkin's Lymphoma (LAM-002A/NHL) (LAM-002A/NHL). U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.